Kuraray Noritake Dental Inc. Overview
Kuraray Noritake Dental is a Japanese dental-materials specialist formed in 2012 by fusing Kuraray's polymer-chemistry dental franchise (CLEARFIL adhesives and composites, PANAVIA resin cements, built on its proprietary MDP adhesive monomer) with Noritake's ceramic franchise (Noritake porcelains, CERABIEN, and the KATANA multilayer zirconia line). The combination gives it an unusual "organic + inorganic" footprint that spans both the dental clinic (adhesion, restoration, cementation) and the dental laboratory (veneering porcelain, zirconia discs and blocks, CAD/CAM materials). Its competitive identity rests on materials science — MDP is now treated as a global reference monomer used across the industry — and on proprietary in-house zirconia powder that enables ultra-fast sintering (a 9-minute chairside cycle for KATANA Zirconia ONE SPEED CROWN). It is a mid-sized, premium, technology-led player rather than a full-line distributor, competing against Ivoclar, Dentsply Sirona, Solventum (ex-3M Oral Care), GC and Tokuyama, and it is strategically backed by Kuraray's balance sheet and global sales network.
What the company does
KND develops, manufactures and sells dental materials and associated devices. Its stated line of business is "dental adhesives and filling materials, dental crown and bridge resin, dental ceramics, dental plaster, dental CAD/CAM devices and materials" (Kuraray press release, 7 Aug 2026; repeated in releases of 2018, 2019 and 2022).
At launch in 2012, the company described its mission as integrating Kuraray Medical's organic dental materials (bonding agents, fillings, facing resin) with Noritake Dental Supply's inorganic materials (crown ceramics, plaster) to develop materials with new functions and to accelerate global expansion beyond Japan (Kuraray press release, 2 Apr 2012).
Business model and revenue model
Revenue model: Overwhelmingly product sales (consumables and semi-finished restorative materials). Kuraray's group revenue recognition policy states that revenue from goods/products is recognized on delivery when the customer obtains control (Kuraray Report 2026, Financial Section, Note 5(5)). No subscription, service or licensing revenue line is disclosed for KND, though KND has an out-licensing programme on its multilayer ceramics patent (EP 2024300) — licensees include 3M (March 2018) and a German competitor (April 2022 settlement). Licensing income amounts are not publicly disclosed.
Product vs. service mix: Not publicly disclosed; independent characterization: >95% product sales, with education (seminars, webinars, hands-on courses) used as a demand-generation tool rather than a monetised service.
Channel: Sales through dental dealers/distributors and Kuraray group sales subsidiaries (Kuraray America, Kuraray Europe GmbH, Kuraray China, Kuraray Noritake Dental Brasil, Kuraray Asia Pacific). Clinical education is delivered in local languages in China and Brazil (Dental Tribune interview, 4 Mar 2026).
Value-chain position
KND sits upstream-to-midstream: it synthesizes key chemistries itself (MDP monomer; in-house zirconia raw powder — "we consistently develop and manage raw material powders in-house", Yamaguchi interview, Mar 2026) and converts them into finished branded consumables. It partners with milling-machine and sintering-furnace makers rather than selling heavy capital equipment itself (CAD/CAM "devices" are part of the licensed line of business, but no major proprietary hardware franchise is evident in recent disclosures).
Customer types and end-markets
| Customer type | Products used | End-market |
|---|---|---|
| General dentists / clinics | CLEARFIL bonds and composites, PANAVIA cements, TEETHMATE, KATANA chairside blocks | Restorative and aesthetic dentistry |
| Dental laboratories / technicians | KATANA Zirconia discs, Noritake/CERABIEN porcelains, plaster and investments | Indirect prosthetics (crowns, bridges) |
| Academic and KOL community | Evidence and education programmes | Opinion leadership, specification |
| OEM / industry (indirect) | MDP technology (licensed/recognized standard) | Adhesive chemistry ecosystem |
Company's own description vs. independent characterization
Company framing: KND emphasizes "durability" (preservation of strength and aesthetics), evidence-based information, and a "Universal Excellence" product concept — versatile materials that reduce components and steps in clinical workflows (Yamaguchi, Dental Tribune, 4 Mar 2026). Its IDS 2025 vision tagline was "The One. All Around." (ZWP Online, 30 Jan 2025).
Independent characterization: KND is a niche-premium materials innovator with two crown-jewel franchises — (1) MDP-based adhesion/cementation and (2) multilayer/high-speed zirconia — that is now pivoting from a Japan-and-Europe premium brand to a capacity-constrained global grower, with North American zirconia block demand as the primary volume driver (Kuraray press releases, 18 Dec 2023 and 7 Aug 2026). It lacks the scale, implant portfolio and equipment ecosystems of Dentsply Sirona or Straumann, and therefore competes on chemistry and quality rather than system lock-in.
Strategy
Stated themes (KND)
From the President's March 2026 interview and IDS 2025 materials:
-
"Universal Excellence" — versatile, high-performance materials that minimize components and procedural steps; IDS 2025 vision "The One. All Around."
-
Durability as core value — long-term preservation of strength and aesthetics in the oral environment.
-
Evidence-based information infrastructure — systematically collecting internal/external data and case studies; multichannel scientific communication (congresses, journals, digital).
-
Global expansion with regional tailoring — Europe as the quality/regulatory anchor; strategic expansion focus on the US, Asia and South America; local-language education in China and Brazil.
-
Supply resilience and capacity — Miyoshi expansion, ultimately aiming to roughly double capacity; tighter manufacturing–R&D feedback loops.
-
Collaborative development with clinicians and environmentally considerate product design (sustainability commitment, unquantified).
-
Bioactive materials — development of products with bioactive properties for long-term predictable treatment (Newsweek/Worldfolio, Sep 2024).
-
Digital/CX — new DX Promotion Department and CX Platform Design Group building CMS/DAM/PIM digital infrastructure (job postings).
Parent strategic frame
Kuraray's medium-term plan "PASSION 2026" (FY2022–FY2026) pursues three challenges: sustainability as an opportunity, innovation from networking, and transformation of people and organization (Kuraray Report 2026). Third-party summaries of the plan identify growing dental materials (including via acquisitions) as a growth priority (roic.ai profile summarizing Kuraray disclosures).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Miyoshi capacity expansion | Decided Dec 2023; started Jun 2026 | +60 t/yr to 300 t/yr; approx. JPY 2.7 bn capex; expandable to 490 t/yr |
| KOL facility at Miyoshi | 2,026 | Top-floor reception and meeting space for visiting international KOLs |
| IDS 2025 launch wave | Mar 2025 | Three new products under "Universal Excellence" |
| Niigata plant transparency programme | Feb 2025 | Published factory video emphasizing hygiene/quality |
| DX / CX organization | 2025–2026 | New department per recruitment listings |
Medium-term targets / guidance
KND: none publicly disclosed. Parent FY2026 guidance: net sales JPY 850.0 bn; operating income JPY 70.0 bn; ordinary income JPY 64.0 bn; net income JPY 40.0 bn; Functional Materials sales JPY 222.0 bn and OI JPY 14.5 bn (assumptions: JPY 150/USD, JPY 175/EUR) (Kuraray Report 2026). Kuraray shareholder-return policy from FY2025: total return ratio of 50% or more with progressive dividends and continuous buybacks (roic.ai summary of Kuraray disclosures).
Products & Services
Note: KND does not publish list prices globally; pricing is dealer-set.
Clinic (organic) materials
| Brand / product | Description | Key capability | Target customer | Launch / latest version | Notes |
|---|---|---|---|---|---|
| CLEARFIL (franchise) | Adhesive and restorative family since 1978 | MDP-based bonding; top Japanese domestic share in bonding agents and fillings (as of 2012) | Dentists | 1978 (CLEARFIL BOND SYSTEM F) | Kuraray release 2 Apr 2012 |
| CLEARFIL Universal Bond Quick 2 | Universal one-bottle adhesive | Rapid application, universal etching modes | Dentists | IDS 2025 | Dental Tribune Mar 2026 |
| CLEARFIL SE BOND / SE BOND 2 | Two-step self-etch adhesive, reference product in literature | MDP self-etch chemistry | Dentists | SE Bond late 1990s; SE Bond 2 mid-2010s | — |
| CLEARFIL MAJESTY family | Resin composites (ES-2, ES Flow etc.) | Shade simplification, aesthetics | Dentists | Ongoing | kuraraynoritake.eu |
| CLEARFIL MAJESTY ES Flow Universal | Flowable composite | Universal shading, simplified workflow | Dentists | IDS 2025 | Dental Tribune Mar 2026 |
| PANAVIA (franchise) | Resin cements built on MDP | Bonds to tooth, metals and zirconia | Dentists | 1980s origin | — |
| PANAVIA V5 | Adhesive resin cement system | Esthetic cementation, wide indication | Dentists | Featured on EU site; mid-2010s | kuraraynoritake.eu |
| PANAVIA SA Cement Universal | Self-adhesive cement | No separate primer needed (claimed) | Dentists | ~2020 | — |
| TEETHMATE (Desensitizer, F-1) | Hypersensitivity / fluoride products; bioactive direction | Calcium-phosphate based sealing | Dentists | — | Bioactive R&D direction per Yamaguchi 2024 |
| Facing resins for crowns and bridges | Indirect composite resins (e.g.; ESTENIA C&B) | Lab veneering | Labs | Ongoing | Line of business |
Laboratory and CAD/CAM (inorganic) materials
| Brand / product | Description | Key capability | Target customer | Launch / latest version | Notes |
|---|---|---|---|---|---|
| KATANA Zirconia (discs) | Multilayer zirconia for lab milling | Four-layer color gradation; precise shrinkage control | Labs | 2,012 | Protected by EP 2024300 |
| KATANA Zirconia high-translucency series (STML/UTML) | Enamel-like translucency for anterior | Aesthetic monolithic restorations | Labs | 2,015 | Kuraray release 2019 |
| KATANA Zirconia YML | Multi-yttria multilayer disc | Upper layers translucent; lower layers higher yttria-differentiated strength | Labs | ~2020 | Dental Tribune Mar 2026 |
| KATANA Zirconia Block | Chairside zirconia blocks | Short treatment times; North American demand driver | Dentists (chairside) | — | Newsweek/Worldfolio Sep 2024 |
| KATANA Zirconia ONE SPEED CROWN | Ultra-fast sintering zirconia | 9-minute sintering via highly activated powder | Dentists (chairside) | Recent | Dental Tribune Mar 2026 |
| CERABIEN ZR | Veneering porcelain for zirconia | Shade matching | Labs | — | — |
| CERABIEN MiLai | New ceramic powder range | "Universal Excellence" porcelain system | Labs | IDS 2025 | Dental Tribune Mar 2026 |
| Noritake Super Porcelain (AAA / EX-3) | Porcelain-fused-to-metal ceramics | Created the modern veneering ceramic category | Labs | 1987 (product naming discrepancy noted) | — |
| Dental plaster and investments | Model and casting materials | Heritage Noritake technology | Labs | 1939 origin | — |
| CAD/CAM devices | Zirconia frame production systems | Historic Noritake CAD/CAM | Labs | Legacy | Line of business |
Services
Hands-on seminars, webinars in local languages (China, Brazil), KOL reception and meeting facilities on the top floor of the new Miyoshi building (opened 2026), journal and congress communication (Kuraray release, 7 Aug 2026; Dental Tribune, Mar 2026). Not monetised separately.
Financial Narrative
Disclosure status for KND
Because KND figures are unavailable, the tables below present the parent, Kuraray Co., Ltd. (consolidated, JGAAP, FY ending 31 Dec, JPY millions) as the financial backstop. Sources: Kuraray Report 2025 and 2026 (11-Year Financial Summary and Financial Section); StockAnalysis.com for gross profit, capex and D&A where cross-checked against Kuraray statements.
Income statement — Kuraray Co., Ltd.
Q1 FY2026 cumulative EPS reported at JPY 6.30 (Matsui Securities data).
Margins — Kuraray Co., Ltd. (%; computed from 6.1)
Revenue CAGR FY2021–FY2025: approx. 6.5% (computed: (808,447/629,370)^(1/4) − 1).
Dividends — Kuraray Co., Ltd.
Source: Kuraray Report 2026, Note 8 (FY2025 year-end JPY 27 proposed to AGM 26 Mar 2026).
Balance sheet — Kuraray Co., Ltd.
Total net assets, longer series (JPY M): FY2021 579602; FY2022 668534; FY2023 736156; FY2024 781790; FY2025 755175 (Kuraray Report 2025/2026). Net debt including lease liabilities per StockAnalysis: FY2021 151641; FY2022 195829; FY2023 147402; FY2024 122590; FY2025 176602.
Ratios — Kuraray Co., Ltd. (computed)
ROIC and cash conversion cycle: not computed (insufficient verified inputs).
Commentary
Parent trend. Kuraray grew sales strongly in FY2021–FY2022 (+16% and +20%) on post-COVID recovery, price pass-through and the full contribution of acquisitions (Calgon Carbon), then plateaued at JPY 780–830 bn. FY2025 was an inflection downward: sales −2.2% and operating income −30.8% to JPY 58.9 bn, as Vinyl Acetate (PVOH, PVB) suffered weak European demand, inventory valuation losses and raw material inflation, and extraordinary impairments (JPY 29.6 bn, chiefly Isoprene Chemicals JPY 15.0 bn and styrenic elastomers JPY 10.6 bn) cut net income 76.5% to JPY 7.5 bn. Free cash flow compressed to JPY 4.4 bn as capex jumped to JPY 94.2 bn while Kuraray simultaneously spent JPY 30.0 bn on buybacks and JPY 17.4 bn on dividends — funded by an increase in short-term borrowings and commercial paper. Leverage remains modest (net debt/EBITDA ~1.2x).
Read-across to KND. The dental business is one of the few positive commentary points in Kuraray's FY2025 review: "Medical" sales of cosmetic dental materials stayed brisk in Europe and the US, with stepped-up marketing. KND is therefore, by inference, a margin-accretive, growth-oriented asset inside a parent whose commodity-exposed businesses are under pressure — a pattern that makes it strategically more important to Kuraray than its likely size suggests. KND's own revenue scale is not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Internal Business Details
| Internal business (characterization) | Contents | Main production site |
|---|---|---|
Organic / clinic materials (ex-Kuraray Medical) | Bonding agents, composite resins, resin cements, desensitizers, facing resins | Niigata Plant (Tainai) |
Inorganic / laboratory and CAD/CAM materials (ex-Noritake Dental Supply) | Zirconia discs and blocks, veneering porcelains, plaster and investments | Miyoshi Plant (Aichi) |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026F |
|---|---|---|---|
Functional Materials net sales (JPY Bn, as reported) | 208.0 | 206.9 | — |
Functional Materials operating income (JPY Bn, as reported) | 12.9 | 10.8 | — |
Functional Materials net sales (JPY Bn, restated new definition) | — | 207.8 | 222.0 |
Functional Materials operating income (JPY Bn, restated new definition) | — | 8.9 | 14.5 |
Functional Materials operating margin (%, as reported) | 6.2 | 5.2 | — |
Segment Revenue
| Segment | FY2024 Sales | FY2025 Sales | FY2024 OI | FY2025 OI | FY2025 % of group sales |
|---|---|---|---|---|---|
Vinyl Acetate | 414.9 | 404.5 | 87.6 | 62.5 | 50.0 |
Isoprene | 76.4 | 80.4 | -9.5 | -4.9 | 9.9 |
Functional Materials (incl. dental) | 208.0 | 206.9 | 12.9 | 10.8 | 25.6 |
Fibers and Textiles | 62.7 | 60.7 | 1.2 | 2.6 | 7.5 |
Trading | 67.6 | 68.8 | 5.9 | 6.0 | 8.5 |
Others | 50.9 | 40.8 | 2.3 | 1.8 | 5.0 |
Elimination & Corporate | -53.5 | -53.7 | -15.4 | -20.1 | — |
Total | 826.9 | 808.4 | 85.1 | 58.9 | 100 |
Knd Metric Details
| KND metric | Status |
|---|---|
EPS, DPS | Not applicable (unlisted) |
Statutory public notice (kessan koukoku) | Japanese companies must publish summarized balance sheets; no KND notice was located in this research — not publicly disclosed |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 629,370 | 756,376 | 780,938 | 826,895 | 808,447 |
Gross profit (JPY Mn) | 204,136 | 241,663 | 239,982 | 267,520 | 246,508 |
Operating income (JPY Mn) | 72,256 | 87,139 | 75,475 | 85,081 | 58,882 |
Depreciation and amortization (JPY Mn) | 59,003 | 65,456 | 77,163 | 85,260 | 84,702 |
EBITDA = OI + D&A (JPY Mn) | 131,259 | 152,595 | 152,638 | 170,341 | 143,584 |
Ordinary income (JPY Mn) | 68,765 | 84,060 | 69,025 | 81,480 | 51,515 |
Income before income taxes (JPY Mn) | 58,696 | 77,995 | 61,273 | 53,176 | 19,821 |
Net income attributable to owners (JPY Mn) | 37,262 | 54,307 | 42,446 | 31,724 | 7,468 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 32.4 | 32.0 | 30.7 | 32.4 | 30.5 |
Operating margin (%) | 11.5 | 11.5 | 9.7 | 10.3 | 7.3 |
EBITDA margin (%) | 20.9 | 20.2 | 19.5 | 20.6 | 17.8 |
Net margin (%) | 5.9 | 7.2 | 5.4 | 3.8 | 0.9 |
Per-Share Data
| Metric | FY2024 | FY2025 |
|---|---|---|
Interim DPS (JPY) | 27 | 27 |
Year-end DPS (JPY) | 27 | 27 |
Annual DPS (JPY) | 54 | 54 |
Balance Sheet
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (JPY Mn) | 1,291,238 | 1,303,511 |
Cash and deposits (JPY Mn) | 118,068 | 104,102 |
Cash and cash equivalents per CF statement (JPY Mn) | 121,692 | 108,314 |
Short-term debt incl. CP and current LTD and bonds (JPY Mn) | 51,996 | 88,732 |
Long-term debt: bonds + long-term borrowings (JPY Mn) | 192,286 | 196,187 |
Total financial debt ex-leases (JPY Mn) | 244,282 | 284,919 |
Net debt ex-leases (JPY Mn) | 122,590 | 176,605 |
Shareholders' equity + AOCI (JPY Mn) | 764,011 | 742,620 |
Total net assets (JPY Mn) | 781,790 | 755,175 |
Goodwill (JPY Mn) | 53,591 | 52,212 |
Total intangible fixed assets incl. goodwill (JPY Mn) | 115,898 | 110,630 |
Working capital: current assets − current liabilities (JPY Mn) | 367,031 | 350,174 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 78,221 | 51,727 | 129,298 | 138,294 | 98,591 |
Capex: purchase of PP&E and intangibles (JPY Mn) | 68,408 | 71,635 | 59,027 | 71,383 | 94,177 |
Free cash flow = OCF − capex (JPY Mn) | 9,813 | -19,908 | 70,271 | 66,911 | 4,414 |
Dividends paid (JPY Mn) | — | — | — | 17,292 | 17,367 |
Share buybacks (JPY Mn) | — | — | — | 20,004 | 30,004 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE (%; NI / avg equity, FY2025 only computable here) | — | 1.0 |
ROA (%; OI / avg total assets) | — | 4.5 |
Current ratio (x) | 2.85 | 2.53 |
Debt / total net assets (x) | 0.31 | 0.38 |
Net debt / EBITDA (x) | 0.72 | 1.23 |
Interest coverage: OI / interest expense (x) | 31.1 | 21.0 |
Asset turnover (x; sales / avg assets) | — | 0.62 |
Region Overview
| Region | Role / trend (company statements) | Source |
|---|---|---|
North America | Fastest-growing zirconia block market; primary rationale for Miyoshi expansion; preference for treatment efficiency | Kuraray releases Dec 2023 and Aug 2026; Yamaguchi Mar 2026 |
Europe | Brisk cosmetic dental sales FY2025; quality/regulatory lead market (MDR); preference for natural aesthetics | Kuraray Report 2026; Yamaguchi Mar 2026 |
Japan | Historic home market; top domestic share in bonding agents and fillings (2012 claim) and leading share in porcelains | Kuraray release Apr 2012 |
China | Regional office; among fastest-growing dental markets; rapid CAD/CAM adoption | Yamaguchi Mar 2026 |
Brazil / South America | Regional office (Kuraray Noritake Dental Brasil); balance of aesthetics and cost | Yamaguchi Mar 2026; CB Insights |
Rest of Asia, Middle East | Covered via Kuraray Asia Pacific (Singapore) and new Kuraray Middle East regional office (2026) | Kuraray news archive 2026 |
Revenue by Region (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Overseas sales ratio (%) | 79.2 | 80.0 |
Japan sales (%; derived as 100 − overseas) | 20.8 | 20.0 |
Capital Markets
| Item | Value | Source / date |
|---|---|---|
Share price | JPY 1,819.5 | StockAnalysis, close 24 Jul 2026 |
Shares issued (end-FY2025) | 307,963 thousand (treasury 924 thousand) | Kuraray Report 2026 |
Market cap (computed at JPY 1,819.5) | approx. JPY 558.6 bn | Computed |
Market cap (third-party, date not stated) | JPY 513.7–523.5 bn | Finboard |
Annual DPS FY2025 | JPY 54 | Kuraray Report 2026 |
Shareholder return policy | Total return ratio ≥50%, progressive dividends, continuous buybacks (from FY2025) | roic.ai summary of Kuraray disclosures |
Buybacks | JPY 20.0 bn (FY2024); JPY 30.0 bn (FY2025); new buyback decision announced Feb 2026 | Kuraray Report 2026; Kuraray news |
Bonds outstanding | JPY 50.0 bn (end-FY2025) | Kuraray Report 2026 |
Capital Markets — Bonds
| Metric | Within 1 yr | 1–2 yrs | 2–3 yrs | 3–4 yrs | 4–5 yrs | Over 5 yrs |
|---|---|---|---|---|---|---|
Bonds (JPY Mn) | 0 | 10,000 | 10,000 | 0 | 20,000 | 10,000 |
Long-term borrowings (JPY Mn) | 32,612 | 17,612 | 23,575 | 30,000 | 10,000 | 65,000 |
Analyst Conclusions
Guidance
KND: no public guidance. Parent FY2026: sales JPY 850 bn (+5.1%), OI JPY 70 bn (+18.9%), NI JPY 40 bn; Functional Materials OI to rise from JPY 8.9 bn (restated) to JPY 14.5 bn.
Bull case
-
Capacity unlocks growth: the June 2026 Miyoshi line (+25% capacity to 300 t/yr, with a path to 490 t/yr) directly targets the fastest-growing demand pocket, North American zirconia blocks.
-
Technology moat: MDP standard status, upheld multilayer IP with licensing income, and 9-minute sintering powder give KND defensible differentiation in both adhesion and ceramics.
-
Strategic value to parent: with Kuraray's commodity segments under pressure (FY2025 OI −30.8%), the brisk-selling dental business is a likely priority for capital and could be re-rated within the group's portfolio.
Bear case
-
Zirconia commoditization: Chinese and European low-cost multilayer discs erode price premiums; litigation history shows sustained imitation.
-
Scale disadvantage: without implants, imaging or proprietary CAD/CAM hardware, KND depends on partners whose ecosystems may favour their own materials.
-
Parent constraints and opacity: Kuraray's lower FY2025 earnings, rising debt and buyback commitments may limit KND's investment pace; lack of disclosure prevents investors from valuing or tracking the business.
Catalysts and monitorables (next 12 months)
-
Kuraray H2/FY2026 results (Feb 2027): any quantified commentary on Medical/dental.
-
Announcement of Kuraray's post-PASSION 2026 medium-term plan (expected late 2026–early 2027), especially any dental growth targets or M&A appetite.
-
Decision on Miyoshi Phase 2 (toward 490 t/yr).
-
New launches ahead of IDS 2027 (Cologne, March 2027).
-
Any change in the Kuraray/Noritake 66.7/33.3 ownership (Noritake is restructuring its own portfolio).
-
Bioactive product launches; patent opposition outcomes.
Analyst verdict
Kuraray Noritake Dental is best understood not as a public company but as a high-quality, privately held technology franchise embedded inside a listed chemical conglomerate. Its value rests on two durable assets: the MDP adhesion platform that underpins CLEARFIL and PANAVIA and has become an industry reference, and a proprietary zirconia materials platform — from raw powder to multilayer design to ultra-fast sintering — that has been commercially validated (KATANA since 2012), legally validated (EP 2024300 upheld in 2021) and monetized (licences to 3M and a German competitor). The company's recent behaviour is that of a business coming out of supply constraint: the 2023 decision and 2026 start-up of a JPY 2.7 bn Miyoshi line, explicitly justified by North American zirconia block demand, plus a stated ambition to roughly double ceramic capacity over time.
The central analytical problem is visibility. No revenue, margin, R&D or headcount data are disclosed, and Kuraray buries dental within a Functional Materials segment dominated by methacrylate and activated carbon. The only hard performance signal is qualitative but meaningful: in a year when Kuraray's operating income fell 31% and net income fell 77%, management singled out dental sales as brisk in Europe and the US. That suggests KND is among the group's healthier, structurally growing businesses.
On balance, KND appears strategically strong and operationally improving, with risks concentrated in zirconia price competition, two-plant concentration in Japan and dependence on its parent's capital allocation during a difficult earnings period. For investors, exposure is only available indirectly through Kuraray (where dental is a minority of earnings) or Noritake (33.3% equity interest). For partners, distributors and competitors, KND should be treated as a premium, IP-protected, capacity-expanding materials specialist whose influence on adhesive and zirconia standards exceeds its size. Any quantitative valuation requires data not currently in the public domain.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles |
|---|---|---|---|
Satoshi Yamaguchi | President (Representative) | From between Aug 2019 and Jul 2021 to present | Kuraray medical development division (R&D); marketing at Kuraray America; development role in Japan; Head of Dental Business, Kuraray Europe (Germany) |
Kiyoyuki Arikawa | Former President | By Sep 2016 – by mid-2021 | — |
Sadaaki Matsuyama | First President (2012); previously President of Kuraray Medical | 2012 – c.2016 | Later Representative Director and Senior Managing Executive Officer of Kuraray; stepped down as Kuraray representative director (announced 27 Nov 2019) |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake |
|---|---|
Kuraray Co., Ltd. | 66.7% |
Noritake Co., Limited | 33.3% |
Competitive Landscape
Key Competitors
| Competitor | Listing | Overlap with KND | Positioning vs. KND |
|---|---|---|---|
Ivoclar Vivadent (Ivoclar Group) | Private (Liechtenstein) | Ceramics (IPS e.max), zirconia, adhesives, composites | Leader in lab ceramics; broader system incl. furnaces |
Dentsply Sirona | NASDAQ: XRAY | CAD/CAM (CEREC), adhesives, cements, zirconia | Much larger; equipment ecosystem; KND zirconia blocks run on partner mills |
Solventum (former 3M Health Care, Oral Care) | NYSE: SOLV | Adhesives (Scotchbond), cements (RelyX), composites (Filtek), zirconia (Lava) | Major adhesive competitor; also a KND patent licensee |
GC Corporation | Private (Japan) | Composites, glass ionomers, cements, ceramics, CAD/CAM | Closest Japanese full-line rival |
Tokuyama Dental (Tokuyama Corp. subsidiary) | Parent TSE: 4043 | Composites (Estelite), adhesives | Japanese composite specialist |
Shofu Inc. | TSE: 7979 | Composites, ceramics, CAD/CAM blocks | Japanese mid-size peer |
Kulzer (Mitsui Chemicals) | Parent TSE: 4183 | Composites, adhesives, lab materials | Owned by another Japanese chemical major |
VOCO GmbH | Private (Germany) | Composites, adhesives, CAD/CAM blocks | Value-oriented clinic materials |
Coltene | SIX: CLTN | Composites, adhesives | Smaller European player |
Envista (Kerr, Nobel) | NYSE: NVST | Adhesives/composites (Kerr), restorative | Broader portfolio incl. implants |
Dentsply/Straumann zirconia & Chinese zirconia makers (e.g., Aidite, Upcera) | Various | Zirconia discs | Price competition in multilayer zirconia |
Kettenbach Dental | Private | Impression materials, restoratives | Partial overlap |



